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ABSTRACT
Increased leukocyte adhesion to vascular endothelium contributes to vaso-occlusion in sickle cell disease. Since nitric oxide bioavailabil-
ity is decreased in sickle cell disease and nitric oxide may inhibit leukocyte adhesion, we investigated whether stimulation of NO-signaling
pathways can reduce the adhesive properties of neutrophils from sickle cell disease individuals (sickle cell diseaseneu). sickle cell dis-
easeneu presented greater adhesion in vitro to both fibronectin and ICAM-1 than control neutrophils. Co-incubation of sickle cell dis-
easeneu with the nitric oxide-donor agents, sodium nitroprusside and dietheylamine NONOate (DEANO), and the guanylate cyclase stim-
ulator, BAY41-2272, all significantly reduced the increased adhesion to fibronectin/ICAM-1. Oxadiazolo[4,3-a]quinoxalin-1-one, a guany-
late cyclase inhibitor, reversed sodium nitroprusside/DEANO-diminished adhesion to fibronectin, implicating cGMP-dependent signaling in
this mechanism. Interestingly, intracellular cGMP was significantly higher in neutrophils from sickle cell disease individuals on hydroxyurea
(sickle cell diseaseHUneu). Accordingly, sickle cell diseaseHUneu adhesion to fibronectin/ICAM-1 was significantly lower than that of sick-
le cell diseaseneu. Agents that stimulate the nitric oxide/cGMP-dependent pathway may have beneficial effects on leukocyte function if
used in these subjects.
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Introduction
Leukocytes play a central role in sickle cell disease (SCD)
pathophysiology. Sickle cell crises are often associated with
infection, neutrophil counts are higher in SCD individuals,
and polymorphonuclear leukocytosis has been correlated
with an increased rate of early death, acute chest syndrome
and stroke.1 There is growing evidence to suggest that leuko-
cytes participate in the initiation and propagation of vaso-
occlusive processes by which the recruitment of large, less
deformable, adherent white cells to the vascular endothelium
and their interaction with circulating erythrocytes may impair
blood flow.2
Neutrophils of SCD individuals are more able to adhere to
fibronectin and to endothelial monolayers than healthy indi-
vidual neutrophils.3 Neutrophils express a variety of adhesion
molecules on their surface that are required for transendothe-
lial migration. The L- and P- selectins mediate tethering and
rolling on the endothelium, while firm adhesion is mediated
by the β2 integrins Mac-1 (CD11b/CD18) and LFA-1
(CD11a/CD18).4 Mac-1 expression has been shown to be
increased on stimulated SCD neutrophils.5,6 Therefore, phar-
macological approaches to inhibit increased leukocyte adhe-
sive interactions may represent important strategies for the
prevention of SCD vaso-occlusion.
Recent reports suggest that nitric oxide (NO) bioavailability
may be decreased in SCD.7 Vascular cell-free hemoglobin,
released during hemolysis, can consume the NO produced by
endothelial cells thus facilitating vasoconstriction and platelet
activation.7 NO is also known to affect adhesion mechanisms.
inhibiting endothelial adhesion molecule expression8 and
reducing the adhesive properties of leukocytes.9
At present, hydroxyurea (HU) is the only widely-used ther-
apy for the treatment of SCD, reducing the frequency of vaso-
occlusive crisis, acute chest syndrome and transfusion, and
increasing fetal hemoglobin (HbF) production in erythroid
cells.10 While it has been proposed that HU induces HbF pro-
duction via tyrosyl radical activation on ribonucleotide reduc-
tase,11 there is evidence to suggest that HU may induce
γ-globin gene expression in erythroleukemic cells and
primary human erythroblasts via a NO-guanylate
cyclase dependent pathway.12,13 Furthermore, data sug-
gest that HU may be oxidized by haem groups to pro-
duce NO in vitro and in vivo,14 suggesting that HU may
act as a donor of NO in vivo.
The aim of this study was to compare the adhesive
properties of neutrophils from SCD individuals with
those on HU therapy. The study also aimed to deter-
mine whether the altered NO bioavailability that is
characteristic of SCD may cause changes in the intracel-
lular levels of NO metabolites and the principal NO sec-
ond messenger, cyclic guanosine monophosphate
(cGMP, produced by the activation of the guanylate
cyclase enzyme). Finally, we determined whether the
adhesive properties of SCD neutrophils may be abro-
gated by pharmacological donation of NO in vitro.
Design and Methods
A total of 52 homozygous HbS/S patients were stud-
ied (19 of whom were on HU therapy). Six patients
were also heterozygous for α-thalassaemia (2 patients
on HU and 4 patients not on HU). Patients were not in
crisis and had not received blood transfusions in the pre-
vious three months. Patients on HU therapy had been
taking 20-30 mg/Kg for at least three months. Twenty-
four healthy individuals were used as controls (age, 20-
50). Informed consent was obtained from all patients
and controls, and the study was approved by the local
ethics committee. For clinical characteristics of all
patients and controls, see Online Supplementary Table 1.
Neutrophils were isolated from peripheral blood15
and static assays15 were performed to determine their
adhesion (2×106 neutrophils/mL RPMI medium) to
immobilised fibronectin (20 µg/mL) or recombinant
ICAM-1 (10 µg/mL) (30 mins., 37°C, 5% CO2). The
adhesion assay and materials used in this study are
described in Supplementary Information. For NO-
donor/drug co-incubation, cells were co-incubated dur-
ing the adhesion assay. 
Total NO metabolites (NOx; nitrite plus nitrate) were
quantified in lysed neutrophil (5×106 cells/mL) ultrafil-
trates using a nitrate/nitrite colorimetric assay kit
(Cayman, Ann Arbor, MI, USA) (see Supplementary
Information). For intracellular cGMP determination,
isolated neutrophils (1×107 cells/ml PBS) were incubat-
ed with a phosphodiesterase inhibitor and cyclic
nucleotides were extracted with perchloric acid (see
Supplementary Information) before quantifying cGMP
using commercially available ELISA kits (Cayman
Laboratories, Ann Arbor, MI, USA).
For flow cytometry, isolated neutrophils (5×106
cells/mL) were incubated with anti-CD11a FITC, anti-
CD11b Alexa Fluor and/or anti-CD49d PE monoclonal
antibody (20 mins., RT, in the dark) and processed as
described in Supplementary Information. Results are
expressed as geometric mean cell fluorescence intensi-
ty values compared to that of isotype controls.
Results are expressed as means ± S.E.M. Statistically
significant differences between groups were deter-
mined using the Mann-Whitney non-parametric test.
The Student’s paired t-test was used to compare groups
before and after treatment with specified drugs.
Statistical significance was established as p<0.05.
Results and Discussion
Leukocyte adhesion to the endothelium of the micro-
circulation plays a key role in SCD vaso-occlusion.2
Therefore, therapeutic approaches to inhibit this adhe-
sion may be important for the prevention of vaso-
occlusion. Figure 1 confirms the increased ability of
neutrophils from SCD individuals (SCDneu) to adhere
to fibronectin, an extracellular matrix component, and
further demonstrates an increased ability of these cells
to adhere to recombinant ICAM-1, an adhesion mole-
cule expressed on activated endothelial cells. Hetero-
zygosity for α-thalassemia did not significantly alter
SCDneu adhesive properties (data not shown).
Decreased NO bioavailability may contribute to the
pathophysiology of SCD.7 Intracellular levels of NOx
were significantly lower in SCDneu compared to levels
in healthy control neutrophils (3.68±0.35 vs. 7.04±1.38
µM/1×106 cells; p<0.05; n=9, respectively), indicating
that reduced NO bioavailability may result in
decreased NO signaling in SCD leukocytes. Intra-
cellular levels of the NO second messenger, cGMP,
however, were not significantly different in SCD and
control neutrophils (0.104±0.023 vs. 0.114±0.021
pMol/1x107 cells; p>0.05; n=19; n=11, respectively).
Whether a reduction in intracellular NO-dependent sig-
naling contributes to the increase in leukocyte adhesive
properties in SCD must still be determined. There is,
however, some evidence that the up regulation of
cyclic adenosine monophosphate (cAMP)-dependent
signaling may contribute to increase the adhesive prop-
erties of SCD neutrophils.15,16 This could be due to aug-
mented serum inflammatory factors in SCD.  
Pharmacological stimulation of the NO-dependent
pathway with the NO donors Diethylamine NONOate
(DEANO; 1 µM) and sodium nitroprusside (SNP; 10
µM) significantly abrogated the adhesion of SCD, but
not control neutrophils (CONneu), to both fibronectin
and ICAM-1 (Figure 2). Furthermore, the NO-inde-
pendent guanylate cyclase activator BAY 41-2272 (150
nM) also significantly decreased SCDneu, but not
CONneu, adhesion to fibronectin and ICAM-1 (Figure
2).  Co-incubation of SCDneu with the NO donors
DEANO (1 µM) or SNP (10 µM), and with the inhibitor
of guanylate cyclase 1H-[1,2,4] Oxadiazolo [4,3-
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a]quinoxalin-1-one (ODQ; 10 µM), prevented the
reduction in SCDneu adhesion to fibronectin that is
induced by these NO donors (Figure 2c), suggesting
that NO donors may reduce SCD neutrophil adhesion
properties via a cGMP-dependent pathway.
The surface expressions of the integrin α-subunits,
CD11a and CD11b, were determined on control and
SCD neutrophils by flow cytometry (Table 1). Data
suggest that the LFA-1 and Mac-1 integrin subunits,
CD11a and CD11b, are not expressed at significantly
different levels on the surface of SCDneu, compared
with CONneu. Some studies have reported an
increased CD11b/CD18 expression on unstimulated
SCD neutrophils,5 while others have detected signifi-
cantly increased CD11b expression only after cell stim-
ulation.6 Integrins can mediate alterations in adhesive
properties both following the mobilization of integrins
to the cell surface and also as a consequence of changes
in integrin affinity and avidity (mediated largely by
integrin clustering).17,18 The affinity of Mac-1 for its lig-
ands, for example, is dynamically regulated by inside-
out signaling, producing a form of the integrin that
binds to its substrate with a much greater affinity.17 It
NO decreases SCD leukocyte adhesive properties in vitro
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Figure 1. Adhesion of neutrophils isolated from control individuals,
steady-state SCD individuals (SCD) and steady-state SCD individu-
als on hydroxyurea therapy (SCDHU; 20-30 mg/kg/day) to
fibronectin (A) and recombinant ICAM-1 (B). Results are expressed
as percentage of adherent cells ± S.E.M. N ≥ 16 and N ≥ 6, for (A)
and (B) respectively. *, p<0.05; ***, p<0.001, compared to control
adhesion; #, p<0.05, compared to SCD adhesion.
Figure 2. Adhesion of neutrophils isolated from control and SCD
individuals to fibronectin (A) and ICAM-1 (B) after or without co-
incubation with 1 µM DEANO, 10 µM SNP or 150 nM BAY 41-
2272. (C) Basal adhesion of SCD neutrophils to fibronectin and
adhesion following co-incubation with 1 µM DEANO, 10 µM SNP
or 150 nM BAY 41-2272 in the presence or absence of the guany-
late cyclase activator, ODQ (10 µM). Results are expressed as per-
centage of adherent cells ± S.E.M. N ≥ 5, N ≥ 3 and N ≥ 8 for (A),
(B) and (C) respectively. (A) and (B): **, p<0.01; ***, p<0.001,
compared to basal control neutrophil adhesion; #, p<0.05; ##,
p<0.01, compared to basal SCD neutrophil adhesion. (C): **,
p<0.01, compared to basal SCD neutrophil adhesion; #, p<0.05,
compared to incubation with DEANO alone; , p<0.05, compared







































































































































































is, therefore, possible that the increased adhesive prop-
erties of SCD neutrophils observed may be mediated
by alterations in integrin affinity rather than expres-
sion. The surface expression of the VLA-4 integrin sub-
unit, CD49d, was also determined on SCDneu, since
the involvement of β1 integrins has been implicated in
neutrophil recruitment during chronic inflammation19
and NO signaling may have a role in controlling VLA-4
integrin expression on the neutrophil cell surface.9 No
significant alteration in CD49d expression was found,
however, on the surface of SCDneu. Interestingly, fol-
lowing incubation with 10 µM SNP (30 mins., 37°C),
the surface expression of the CD11a subunit was sig-
nificantly decreased on both SCD and SCDHU neu-
trophils to levels similar to those of CONneu (Table 1).
However, incubation with a NO donor did not
decrease the surface expression of the major neutrophil
integrin Mac-1, as demonstrated by the unaltered
CD11b expression following incubation with SNP. 
Data indicate that a reduction in adhesion molecule
expression may not contribute significantly to the
reduction in SCD neutrophil adhesion mediated by NO
donors. Instead, these agents may abrogate SCD neu-
trophil adhesion via alterations in the function (via
affinity or avidity alterations) of the adhesion mole-
cules already expressed on the cell surface. Similarly,
NO-dependent signaling has been shown to alter
platelet GPIIb/IIIa integrin function, as well as neu-
trophil Mac-1 integrin affinity or avidity.9,20
Interestingly, the adhesion of neutrophils from SCD
individuals on HU therapy (SCDHUneu) demonstrated
a significantly lower adhesion to fibronectin and
ICAM-1 that approached that of CONneu adhesion
(Figure 1). NOx in these cells were not found to be sig-
nificantly higher than in SCDneu (SCDHUneu;
4.22±0.92 µM/1×106 cells; p>0.05; n=11). However,
intracellular cGMP levels were found to be approxi-
mately doubled in SCDHUneu compared with control
and SCD neutrophils (0.241±0.034 pMol/1×107 cells;
p<0.001; n=9).
The surface expressions of the CD11a, CD11b and
CD49d integrin subunits were not found to be altered
significantly on SCDHUneu, indicating that HU therapy
may reduce neutrophil adhesion via alterations in inte-
grin affinity / avidity, as also observed when SCD neu-
trophils were treated with NO donors. Alternatively,
the possibility that SCD neutrophil adhesion may be
mediated by receptors other than those studied here
should not be ruled out. Since activation of cGMP-
dependent signaling was found to reduce SCDneu
adhesive properties, it is possible that the increased
intracellular cGMP levels observed in SCDHUneu may
contribute to the observed reduction in adhesion. These
results provide further evidence to support the hypoth-
esis that HU may exert some of its effects via up regu-
lation of NO-cGMP signaling. Indeed, HU has been
reported to induce NO-cGMP signaling in endothelial
cells14 and cGMP levels have been found to be increased
in the plasma and red cells of SCD individuals on
HU.21,22 Furthermore, HU may increase NO bioavailabil-
ity by decreasing hemolysis and, in turn, decreasing NO
scavenging by cell-free plasma hemoglobin and arginine
scavenging by cell-free arginase.7 The correlation of
SCD/SCDHU neutrophil adhesiveness to markers of
the hemolytic rate, hemoglobin levels and reticulocyte
counts did not, however, reveal any significant associa-
tions with hemolytic rate (results not shown). While HU
may mediate a reduction in leukocyte adhesion by
increasing intracellular cGMP levels, other mechanisms
may also participate in the HU-mediated effect. In
accordance with evidence that intracellular cAMP may
participate in increased SCD neutrophil adhesive prop-
erties,15 cAMP levels were found to be reduced in SCD
patients on HU therapy16 and it is possible that cross talk
between the cAMP and cGMP pathways may result in
alterations in the cyclic nucleotide balance with a conse-
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Table 1. Expressions of integrin a-subunits on the surface of neutrophils isolated from control individuals, steady-state SCD individuals
(SCD) and steady-state SCD individuals on hydroxyurea therapy (SCDHU; 20-30 mg/kg/day). 
Control SCD SCDHU
Integrin α-subunit
MFI p   MFI P MFI p
(N=7) (N=8) (N=8)
CD11a Basal 13.82±1.66 16.03±1.27 17.05±1.47
SNP 11.55±1.27 >0.05 11.66±0.77 0.0002 14.70±1.50 0.035
CD11b Basal 162.9±47.8 151.23±32.4 154.0±46.9
SNP 191.37±41.8 >0.05 184.73±21.58 >0.05 207.96±33.04 >0.05
CD49d Basal 7.73±0.72 9.81±0.80 10.53±1.22
SNP 7.28±0.59 >0.05 10.03±1.06 >0.05 10.43±1.34 >0.05
Neutrophil surface integrin expressions were determined under basal conditions (basal) and following incubation with 10 µM SNP (SNP; 30 min.; 37°C). Surface
expression is reported as mean fluorescence intensity (MFI) on 10,000 cells and results are presented as the mean ± SEM of n individuals. P values compare SNP-incu-
bated expression to basal expression (paired t-test). No significant differences were found between surface integrin expressions for the control, SCD and SCDHU groups
(unpaired t-test). 
quent reduction in SCD neutrophil adhesive function.
Our data suggest that although decreased NO
bioavailability may not play a major role in the increased
adhesive properties of SCD leukocytes, pharmacological
stimulation of the cGMP-dependent pathway may be a
potential approach for reducing neutrophil adhesion to
the vascular endothelium. A number of NO-donating
agents and drugs that stimulate cGMP accumulation
show potential for use in vivo. Guanylate cyclase
inhibitors, such as BAY 41-2272, have been successfully
used to treat animal models of cardiovascular disease,
pulmonary hypertension and inflammation.23-25
Alternatively, drugs that have a more cell-specific effect,
such as inhibitors of phosphodiesterases (PDE) may
prove more effective in specifically reversing altered
SCD neutrophil function. For example, sildenafil, a
PDE5-specific inhibitor, is being tested clinically in SCD
patients with pulmonary hypertension26 and should it be
found that this or any other PDE is expressed in leuko-
cytes, such PDE inhibitors may also have the potential
for abrogating altered SCD neutrophil adhesion. 
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